31 The salient findings in our current study are: Comparison of the mean headache severity decrement between sodium valproate

and Sumatriptan at half an hour, one hour, and 2 hours after administration showed that sodium valproate was as effective as Sumatriptan for headache relief. Sodium valproate was more effective than Sumatriptan in decreasing the associated symptoms. The side effects of sodium valproate were significantly fewer than those of Sumatriptan.  In previous studies that similarly used intravenous sodium valproate, no significant side effects were reported.19-22 The only report for side effects was made by the Shahien R et al.23 study (2011): photophobia (67%); unilateral #SB939 molecular weight keyword# pain (50%); vomiting (41%); phonophobia (39%); and pulsatile pain (36%). In that study, the loading dose of sodium valproate was 900-1200 mg. Consequently, the difference between the dosage in that study and ours (400 mg) may explain the conflicting results. The prescribed dose of sodium valproate, i.e., Inhibitors,research,lifescience,medical 400 mg, seems appropriate for relieving acute migraine attacks. In the Sumatriptan group, the improvement rates of nausea, photophobia, and phonophobia were very low Inhibitors,research,lifescience,medical compared to those reported previously.27 It seams that the main reasons for this discrepancy are genetic

and ethnic differences. All the patients without nausea and vomiting who received Sumatriptan developed nausea and vomiting. Thus, it seems that sodium Inhibitors,research,lifescience,medical valproate may be more effective than Sumatriptan in patients presenting without nausea and vomiting.  Given that Sumatriptan has more side effects and administration limitations, the following findings

of our study highlight the advantage of sodium valproate over Sumatriptan in the treatment of acute migraine attacks: Sodium valproate has similar effectiveness compared to Sumatriptan. Sodium valproate is more efficacious in alleviating headache-associated symptoms. Sodium valproate can replace Sumatriptan in patients with contraindications for Sumatriptan use. Sodium Inhibitors,research,lifescience,medical valproate has fewer side effects. Conclusion Our study suggests that 400 mg of intravenous sodium valproate is effective in the treatment of acute migraine headache, particularly in patients not on sodium valproate prophylaxis or in patients with contraindications for Sumatriptan use. Conflict of Interest: None declared.
Background: The United Nations has predicted GPX6 that the population of slum dwellers will have grown from one billion people worldwide to 2 billion by 2030. This trend is also predictable in Iran. In the Iranian metropolis of Shiraz, more than 10% of the residents live in slum areas. There are several problems regarding the delivery of social services in these areas. The aim of this study was to evaluate slums dwellers’ access to and coverage of health care. Methods: This cross-sectional face-to-face study included 380 household of slum dwellers via stratified random sampling.